These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 1457345

  • 1. Enhancement of the cytotoxicity of SR 4233 to normal and malignant tissues by hypoxic breathing.
    Minchinton AI, Brown JM.
    Br J Cancer; 1992 Dec; 66(6):1053-8. PubMed ID: 1457345
    [Abstract] [Full Text] [Related]

  • 2. Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU-2285 in combination with single and fractionated irradiation.
    Shibata T, Shibamoto Y, Sasai K, Oya N, Murata R, Takagi T, Hiraoka M, Abe M.
    Jpn J Cancer Res; 1996 Jan; 87(1):98-104. PubMed ID: 8609056
    [Abstract] [Full Text] [Related]

  • 3. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
    Brown JM.
    Br J Cancer; 1993 Jun; 67(6):1163-70. PubMed ID: 8512801
    [Abstract] [Full Text] [Related]

  • 4. Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233.
    Zeman EM, Hirst VK, Lemmon MJ, Brown JM.
    Radiother Oncol; 1988 Jul; 12(3):209-18. PubMed ID: 3175048
    [Abstract] [Full Text] [Related]

  • 5. SR 4233: a tumor specific radiosensitizer active in fractionated radiation regimes.
    Brown JM, Lemmon MJ.
    Radiother Oncol; 1991 Jul; 20 Suppl 1():151-6. PubMed ID: 2020764
    [Abstract] [Full Text] [Related]

  • 6. Reoxygenation and rehypoxiation in the SCCVII mouse tumor.
    Kim IH, Brown JM.
    Int J Radiat Oncol Biol Phys; 1994 Jun 15; 29(3):493-7. PubMed ID: 8005805
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen.
    Dorie MJ, Menke D, Brown JM.
    Int J Radiat Oncol Biol Phys; 1994 Jan 01; 28(1):145-50. PubMed ID: 8270435
    [Abstract] [Full Text] [Related]

  • 8. Interaction of SR-4233 with hyperthermia and radiation in the FSaIIC murine fibrosarcoma tumor system in vitro and in vivo.
    Herman TS, Teicher BA, Coleman CN.
    Cancer Res; 1990 Aug 15; 50(16):5055-9. PubMed ID: 2379171
    [Abstract] [Full Text] [Related]

  • 9. Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. I. Tirapazamine.
    Olive PL.
    Br J Cancer; 1995 Mar 15; 71(3):529-36. PubMed ID: 7880735
    [Abstract] [Full Text] [Related]

  • 10. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells.
    Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW.
    Int J Radiat Oncol Biol Phys; 1986 Jul 15; 12(7):1239-42. PubMed ID: 3744945
    [Abstract] [Full Text] [Related]

  • 11. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model.
    Kyle AH, Minchinton AI.
    Cancer Chemother Pharmacol; 1999 Jul 15; 43(3):213-20. PubMed ID: 9923551
    [Abstract] [Full Text] [Related]

  • 12. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation.
    Brown JM, Lemmon MJ.
    Int J Radiat Oncol Biol Phys; 1991 Mar 15; 20(3):457-61. PubMed ID: 1995531
    [Abstract] [Full Text] [Related]

  • 13. Second-generation 1,2,4-benzotriazine 1,4-di-N-oxide bioreductive anti-tumor agents: pharmacology and activity in vitro and in vivo.
    Minchinton AI, Lemmon MJ, Tracy M, Pollart DJ, Martinez AP, Tosto LM, Brown JM.
    Int J Radiat Oncol Biol Phys; 1992 Mar 15; 22(4):701-5. PubMed ID: 1544841
    [Abstract] [Full Text] [Related]

  • 14. Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro.
    Siim BG, van Zijl PL, Brown JM.
    Br J Cancer; 1996 Apr 15; 73(8):952-60. PubMed ID: 8611431
    [Abstract] [Full Text] [Related]

  • 15. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
    Siim BG, Pruijn FB, Sturman JR, Hogg A, Hay MP, Brown JM, Wilson WR.
    Cancer Res; 2004 Jan 15; 64(2):736-42. PubMed ID: 14744792
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice.
    Walton MI, Workman P.
    J Pharmacol Exp Ther; 1993 May 15; 265(2):938-47. PubMed ID: 8496834
    [Abstract] [Full Text] [Related]

  • 17. Aerobic radiosensitization by SR 4233 in vitro and in vivo.
    Zeman EM, Lemmon MJ, Brown JM.
    Int J Radiat Oncol Biol Phys; 1990 Jan 15; 18(1):125-32. PubMed ID: 2298615
    [Abstract] [Full Text] [Related]

  • 18. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors.
    Brown JM, Lemmon MJ.
    Cancer Res; 1990 Dec 15; 50(24):7745-9. PubMed ID: 2253217
    [Abstract] [Full Text] [Related]

  • 19. The effect of pH on the aerobic and hypoxic cytotoxicity of SR4233 in HT-29 cells.
    Skarsgard LD, Skwarchuk MW, Vinczan A, Chaplin DJ.
    Br J Cancer; 1993 Oct 15; 68(4):681-3. PubMed ID: 8398693
    [Abstract] [Full Text] [Related]

  • 20. Carbogen breathing after irradiation enhances the effectiveness of tirapazamine in SiHa tumors but not SCCVII tumors in mice.
    Minchinton AI, Tonn DA, Sutherland DP, Kyle AH.
    Radiat Res; 2002 Jul 15; 158(1):94-100. PubMed ID: 12071808
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.